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Ho
pa
MaOBJECTIVES The purpose of this study was to evaluate 15-year patency and life expectancy after endovascular
treatment (EVT) with primary stenting guided by intravascular ultrasound (IVUS) for iliac artery lesions.
BACKGROUND Fifteen-year patency, factors causing restenosis, and survival after IVUS-guided EVT are unclear based
on the TransAtlantic Inter-Society Consensus II (TASC-II) classiﬁcation in peripheral arterial disease (PAD).
METHODS EVT was performed for 507 lesions in 455 patients with PAD. The 15-year endpoints were primary, primary-
assisted, and secondary patency; overall survival; freedom from major adverse cardiovascular events (MACE); and
freedom from major adverse cardiovascular and limb events (MACLE).
RESULTS The 5-, 10-, and 15-year primary and secondary patencies were 89%, 83%, and 75%, respectively, and 92%,
91%, and 91%, respectively. There were no signiﬁcant differences among TASC-II categories.
CONCLUSIONS IVUS-guided stenting for the iliac artery had favorable 15-year patency in all TASC categories. Life
expectancy after EVT was poor, but stenting is feasible for patients with PAD. (J Am Coll Cardiol Intv 2015;8:1893–901)
© 2015 by the American College of Cardiology Foundation.T he therapeutic strategy for peripheral arterialdisease (PAD) is generally selected based onthe lesion type, using the morphological
stratiﬁcation in the Inter-Society Consensus for
the Management of Peripheral Arterial Disease
(TransAtlantic Inter-Society Consensus [TASC]) clas-
siﬁcation in the aortoiliac artery (1). Favorable results
have been obtained with endovascular treatment
(EVT) for iliac artery lesions compared with lesions
of the femoral artery (2–4). However, there are fewm the Department of Vascular Medicine, Vascular Center, Cardiovascular
spital), Shibukawa, Gunma, Japan. The authors have reported that they h
per to disclose.
nuscript received April 22, 2015; revised manuscript received August 7, 2reports on very long-term patency after treatment of
TASC type A to D lesions.
Intravascular ultrasound (IVUS) gives a high-
resolution cross-sectional image for use during coro-
nary and peripheral intervention, and the additional
morphological information may decrease the reste-
nosis rate after stent implantation (5–8). However,
factors evaluated by IVUS that cause restenosis in
long-term patency after EVT have not been analyzed
in detail. PAD is a systemic disease with multipleHospital of Central Japan (Kitakanto Cardiovascular
ave no relationships relevant to the contents of this
015, accepted August 13, 2015.
TABLE 1 Baseline Clinical Chara
Factor
All
(N
Number of lesions
Age, yrs 71.
Male 39
Fontaine class, IIa/IIb/III/IV 128/
CLI 53
Lesion length, cm 5.
Chronic total occlusion 11
Lesion location
Common iliac artery 20
External iliac artery 24
Common to external
iliac artery
54
Aortoiliac artery 1
Initial success 49
Number of stents 1.23
Stent type
Balloon expandable 98
Self-expandable 39
Both 1
ABI
Pre-procedure 0.5
Post-procedure 0.9
Angiographic stenosis, %
Pre-procedure 78.
Post-procedure 14.
IVUS MLA, mm2
Pre-procedure 10
Post-procedure 34.
Calciﬁed lesion 9
Stent edge dissection 9
In-stent thrombosis 1
Stent fracture 6
Antiplatelet discontinuation 1
SEE PAGE 1902
ABBR EV I A T I ON S
AND ACRONYMS
CLI = critical limb ischemia
CTO = chronic total occlusion
EVT = endovascular treatment
IVUS = intravascular
ultrasound
MACE = major adverse
cardiovascular event(s)
MACLE = major adverse
cardiovascular and limb event(s)
MLA = mean stent lumen area
PAD = peripheral arterial
disease
TASC = TransAtlantic
Inter-Society Consensus
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1894atherosclerotic risk factors and poor long-
term survival (1,9,10), and more information
is needed on long-term outcomes after
EVT for PAD. Therefore, in this study, we
analyzed 15-year patency and life expectancy
after IVUS-guided primary stenting for iliac
artery lesions categorized using the TASC
classiﬁcation.
METHODS
PATIENTS. Patients with PAD admitted to
Kitakanto Cardiovascular Hospital from June
1993 to December 2013 for EVT for subjective
symptoms categorized as higher than Fon-
taine class II and with stenosis of the iliacartery $70% in angiography were included in a
single-center prospective study. Written informed
consent for participation in the study was obtained
from all patients, and the protocol was approved bycteristics
Patients
¼ 455)
Type A/B
(n ¼ 312)
Type C/D
(n ¼ 143) p Value
507 364 (A/B: 231/133) 143 (C/D: 53/90)
8  8.5 71.9  8.3 71.6  9.0 0.728
9 (87.7) 275 (88.1) 124 (86.7) 0.667
274/5/48 117/171/2/22 11/103/3/26 <0.001
(11.6) 24 (7.7) 29 (20.2) <0.001
8  4.9 4.2  3.7 9.9  5.2 <0.001
9 (23.5) 50 (13.7) 69 (48.3) <0.001
1 (39.6) 169 (46.4) 32 (22.4) <0.001
0 (47.3) 195 (53.6) 45 (31.5) <0.001
(10.7) 0 (0) 54 (37.8) <0.001
2 (2.4) 0 (0) 12 (8.4) <0.001
3 (97.2) 359 (98.62) 134 (93.3) 0.002
 0.20 1.07  0.26 1.63  0.59 <0.001
<0.001
(19.3) 92 (25.2) 6 (4.2)
2 (77.3) 269 (73.9) 123 (86.0)
7 (3.4) 3 (0.8) 14 (9.8)
9  0.02 0.63  0.21 0.50  0.26 <0.001
0  0.02 0.93  0.20 0.87  0.26 0.006
5  16.0 75.6  15.0 85.8  16.1 <0.001
0  9.5 13.0  9.3 16.7  9.6 <0.001
.3  8.5 11.6  8.6 6.9  6.9 <0.001
9  11.9 36.8  12.3 30.0  8.9 <0.001
7 (19.1) 66 (18.1) 31 (21.6) 0.361
(1.8) 6 (1.6) 3 (2.1) 0.730
1 (2.2) 4 (1.1) 7 (4.9) 0.021
(1.2) 5 (1.4) 1 (0.7) 0.861
2 (2.4) 9 (2.6) 3 (2.1) 0.940
Continued on the next pageour institutional ethical committee before initiation
of the study (4). A total of 874 patients were treated
for infrarenal aortoiliac disease. Of these patients,
194 with intermittent claudication were treated
with exercise rehabilitation and medication alone (1).Revascularization was performed in 680 patients with
critical limb ischemia (CLI) or intermittent claudica-
tion whose symptoms were not improved or deterio-
rated after medication. EVT was performed for all
type A and B lesions. Of patients with type C lesions,
4 with iliac lesions and severe calciﬁed stenosis in
the common femoral artery were excluded because
EVT and endarterectomy were performed concur-
rently. Of patients with type D lesions, 18 were
excluded because of severe calciﬁed stenosis in the
common femoral artery, asmentioned in the preceding
text (n¼ 2), abdominal aortic aneurysm requiring stent
graft placement (n ¼ 4), severe calciﬁed aortoiliac oc-
clusion (n ¼ 9), and aortoiliac occlusion requiring
concomitant femoropopliteal bypass (n ¼ 3). As a
result, EVT was performed in 658 patients, of whom
203 were excluded because of treatment with angio-
plasty alone (n ¼ 169; types A: 98, B: 57, C: 12, D: 2),
restenotic lesions (n ¼ 29), and primary stenting
without adequate IVUS data (n ¼ 5). Therefore, anal-
ysis of endpoints was ﬁnally performed in 455 patients
who underwent primary stenting for de novo aortoiliac
lesions.
ENDOVASCULAR TREATMENT. All patients received
a bolus of 5,000 IU of heparin before treatment. The
puncture site for arterial access was in the inguinal
region of the femoral arteries, and EVT was performed
through the iliac artery via an ipsilateral or contralat-
eral route. All procedures for stent implantation were
guided by IVUS. Images were acquired with an IVUS
console (Volcano s5 Imaging system, Volcano Corp.,
San Diego, California, or CVIS, Boston Scientiﬁc, San
Jose, California) and an IVUS catheter (Visions PV .018,
20MHz, Volcano Corp., or Ultracross catheter, 30MHz,
Boston Scientiﬁc). After guidewire passage through
the lesion, IVUS was performed at the lesion segment
and at proximal and distal reference sites in the lesion
segment with manual pullback. A lesion was classiﬁed
as calciﬁed on the basis of IVUS identiﬁcation of an
angle of calciﬁcation >180 in the plaque in the mini-
mal lesion area. In caseswith severely calciﬁed lesions,
minimal pre-dilation with balloon angioplasty was
performed with Sterling or Wanda (Boston Scientiﬁc,
Natick, Massachusetts) and Powerﬂex (Cordis, Fre-
mont, California) balloon catheters. In most other
cases, direct stent implantation was performed using
TABLE 1 Continued
Factor
All Patients
(N ¼ 455)
Type A/B
(n ¼ 312)
Type C/D
(n ¼ 143) p Value
Risk factors
Diabetes mellitus 128 (28.1) 94 (30.1) 34 (23.8) 0.162
Hypertension 303 (66.6) 213 (68.3) 90 (62.9) 0.263
Coronary artery disease 190 (41.8) 134 (42.9) 56 (39.2) 0.447
Cerebral infarction 79 (17.4) 54 (17.3) 25 (17.5) 0.964
Smoking 380 (83.5) 259 (83.0) 121 (84.6) 0.669
Hemodialysis 26 (5.7) 15 (4.8) 11 (7.7) 0.218
Laboratory data
eGFR, ml/min/1.73 m2 57.5  23.6 56.6  20.6 59.6  29.8 0.214
Total-C, mg/dl 194  39 194  39 193  40 0.801
LDL-C, mg/dl 118  34 119  31 117  39 0.557
HDL-C, mg/dl 47.5  15.2 47.6  15.9 47.3  13.2 0.844
Triglyceride, mg/dl 151  90 153  86 148  99 0.584
D-dimer, mg/dl 1.4  1.5 1.3  1.4 1.5  1.8 0.198
Fibrinogen, mg/dl 327  99 319  89 346  118 0.007
TAT, ng/ml 5.2  7.2 5.3  7.2 5.1  7.2 0.783
PIC, mg/ml 1.0  0.5 0.9  0.5 1.1  0.6 0.002
C-reactive protein, mg/dl 0.62  1.23 0.44  0.73 1.01  1.87 <0.001
Drugs
Aspirin 313 (68.8) 211 (67.6) 102 (71.3) 0.429
Thienopyridines 162 (35.6) 119 (38.1) 43 (30.1) 0.095
Cilostazol 207 (45.5) 150 (48.1) 57 (40.0) 0.102
Beraprost 197 (43.3) 144 (46.1) 53 (37.1) 0.069
Sarpogrelate 19 (4.2) 15 (4.8) 4 (2.8) 0.458
Statin 157 (34.5) 101 (32.4) 56 (39.2) 0.157
ACE/ARB 186 (40.9) 134 (42.9) 52 (36.4) 0.185
b-blocker 55 (12.1) 43 (13.8) 12 (8.4) 0.102
Ca antagonist 260 (57.1) 187 (59.9) 73 (51.0) 0.075
Values are mean  SD or n (%).
ABI ¼ ankle brachial pressure index; ACE ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin re-
ceptor blocker; CLI ¼ critical limb ischemia; eGFR ¼ estimated glomerular ﬁltration rate; HDL-C ¼ high density
lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol; MLA ¼mean lumen area; PIC ¼ plasmin-a2
plasmin inhibitor complex; TAT ¼ thrombin-antithrombin complex; Total-C ¼ total cholesterol.
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1895Palmaz, SMART (Cordis), Wallstent RP, Express LD
(Boston Scientiﬁc), and Luminexx (Bard Inc, Murray
Hill, New Jersey) stents. For balloon-expandable
stents, a stent diameter equivalent to the reference
diameter was selected, whereas for self-expandable
stents, a diameter 1 mm larger than the reference
diameter was chosen. Expansion after stent implan-
tation was performed by adjusting the balloon diam-
eter and inﬂation pressure to minimize the difference
between the arterial wall in the proximal and distal
areas of the lesion and stent, guided by IVUS. If vessel
dissection was found at the stent edges, another stent
was added over the dissection. Minimal in-stent
thrombus protrusion was identiﬁed in the same way.
If a large thrombus protrusion was found in the stent,
further ballooning or aspiration was added over the
thrombus protrusion.
After EVT, the mean value of the 3 stent areas
(proximal, middle, and distal) was calculated to give
the mean stent lumen area (MLA). Measurements of
the proximal and distal regions were performed at
points deﬁned as 10% of the stent length toward the
center from the stent ends (7). Cross-sectional areas
of the vessels and stents were determined using
software on the IVUS display by 2 technologists who
were blinded to the EVT procedure.
DRUG ADMINISTRATION. Administration of oral
drugs (cilostazol, beraprost, sarpogrelate) for treat-
ment of PAD was continued and oral aspirin, clopi-
dogrel or ticlopidine was added as antiplatelet
treatment for more than 3 days before EVT. Patients
with side effects such as bleeding, appetite loss,
headache, or palpitation were treated with only 1
agent. Drugs for hypertension and hyperlipidemia
that were used before EVT were also administered
continuously.
RISK FACTORS. Blood was collected during fasting in
the morning to determine levels of total cholesterol,
low-density lipoprotein cholesterol, high-density li-
poprotein cholesterol, triglyceride, albumin, glucose,
glycosylated hemoglobin A1c, creatinine, ﬁbrinogen,
D-dimer, thrombin-antithrombin complex, andplasmin-
a2 plasmin inhibitor complex. Diabetes mellitus,
hypertension, coronary artery disease, and cere-
bral infarction were examined as risk factors for arte-
riosclerosis. Lipid abnormalities were diagnosed based
on treatment with lipid-lowering agents; or
low-density lipoprotein cholesterol $140 mg/dl,
high-density lipoprotein cholesterol <40 mg/dl, or
triglyceride $150 mg/dl (1,11).
DATA ANALYSIS AND ENDPOINTS. Pre- and post-
operative rates of stenosis for the reference diameterwere calculated after performing digital subtraction
angiography (Philips Medical Systems, Best, the
Netherlands) in 2 directions, using software from the
manufacturer. Cases with post-operative residual
stenosis <30% were classiﬁed as an initial success.
Patients were followed up at 1, 3, and 6 months after
EVT and then evaluated at 4- or 6-month intervals at
an ofﬁce visit (12). Restenosis in the follow-up period
was deﬁned as a decrease in the ankle brachial pres-
sure index of $0.1 and a peak systolic velocity ratio
>2.4 on duplex ultrasonography or $50% stenosis
on angiography (13). Vital status and status of medi-
cations were assessed using hospital records and
written questionnaires completed at the Foot Care
Club in our hospital or in response to an invitation
letter (14). Cases in which expansion could not be
performed because a guidewire could not be passed
through the lesion were excluded from the analysis of
long-term patency. Patency rates are expressed as
primary (deﬁned as patency of the target lesion during
FIGURE 1 Kaplan-Meier Analysis of Primary, Primary-Assisted, and
Secondary Patency Rates
Patency rates are after primary stenting in all patients. p. ¼ patency.
FIGURE 2 Kaplan-
(A) Kaplan-Meier ana
signiﬁcant difference
lesions. There was n
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1896follow-up), primary-assisted (deﬁned as patency of
the target lesion following EVT at the target vessel site
in case of symptomatic restenosis, but without occlu-
sion at any time), and secondary (deﬁned as patency of
the target lesion after treatment of a (re)occlusion,
with patency ending with an untreated or surgically
treated occlusion) (15,16). The endpoints of life ex-
pectancy were overall survival, freedom from majorMeier Analysis of the Primary Patency Rate After Primary Stenting
lysis of the primary patency rate after primary stenting, based on the TransAtl
s among type A to type D lesions (p ¼ 0.149). (B) Kaplan-Meier analysis of the
o signiﬁcant difference between the 2 groups (p ¼ 0.406).adverse cardiovascular events (MACE) (all-cause
death, myocardial infarction, cardiac revasculariza-
tion, and stroke), and freedom from major adverse
cardiovascular and limb events (MACLE) (MACE, any
repeat revascularization for limb, and major amputa-
tion). Myocardial infarction was deﬁned as detection
of an increase in cardiac troponin and/or creatine
phosphokinase during: 1) symptoms of myocardial
ischemia; 2) new (or presumably new) signiﬁcant
electrocardiographic ST-segment/T-wave changes or
left bundle branch block; 3) development of patho-
logical electrocardiographic Q waves; 4) new loss of
viable myocardium or regional wall motion abnor-
mality identiﬁed by an imaging procedure; or 5) iden-
tiﬁcation of intracoronary thrombus by angiography or
at autopsy (17). Cardiac revascularization was deﬁned
as a history of percutaneous coronary intervention or
coronary artery bypass graft surgery. Stroke was
deﬁned as a hospital or neurologist report of diagnosis
of ischemic stroke or transient ischemic attack.
Major amputation was deﬁned as above-the-ankle
amputation.
STATISTICAL ANALYSIS. Follow-up times are
expressed as medians. Continuous variables are
expressed as mean  SD, and were compared by
Student t test. Proportions were compared by chi-
square test with Yates’ correction. The Kaplan-Meier
method was used to determine patencies and sur-
vival in the follow-up period, and a log-rank test was
performed for comparison of lesion types. The hazard
ratio and conﬁdence intervals were calculatedantic Inter-Society Consensus II (TASC-II) classiﬁcation. There were no
primary patency rate after primary stenting in type A/B and type C/D
TABLE 2 Predictive Risk for Restenosis After EVT by
Cox Univariate and Multivariate Analysis
Risk Factor HR 95% CI p Value
Univariate analysis
Age, yrs 0.974 0.943–1.007 0.117
Male 1.311 0.520–3.309 0.566
ABI pre-procedure 0.226 0.043–1.180 0.078
ABI post-procedure 0.326 0.040–2.668 0.296
CLI 1.067 0.383–2.977 0.901
TASC, A/B/C/D 1.158 0.897–1.495 0.261
Lesion length, cm 1.060 1.019–1.102 0.004
Lesion location
Common iliac artery 0.706 0.383–1.302 0.265
External iliac artery 1.356 0.750–2.452 0.313
Common to external iliac
artery
1.683 0.663–4.271 0.273
Aortoiliac artery 1.094 0.148–8.028 0.930
Number of stents 0.877 0.427–1.798 0.720
Stent type, balloon/self 0.836 0.424–1.676 0.617
Angiographic stenosis, %
Pre-procedure 1.026 1.005–1.007 0.017
Post-procedure 1.040 1.009–1.071 0.010
IVUS MLA, mm2
Pre-procedure 0.934 0.885–0.985 0.012
Post-procedure 0.956 0.920–0.993 0.021
Calciﬁed lesion 2.449 1.214–4.940 0.012
Stent fracture 2.754 0.667–11.374 0.162
Stent edge dissection 1.552 0.213–11.333 0.665
In-stent thrombosis 9.055 3.504–23.403 <0.001
Antiplatelet discontinuation 8.384 2.581–27.230 <0.001
Risk factors
Diabetes mellitus 1.442 0.846–2.460 0.179
Hypertension 0.833 0.414–1.674 0.607
Coronary artery disease 0.836 0.352–1.150 0.134
Cerebral infarction 1.084 0.509–2.308 0.835
Smoking 0.931 0.437–1.983 0.853
Dyslipidemia 1.506 0.854–2.654 0.157
Hemodialysis 2.458 0.853–7.000 0.092
Laboratory data
eGFR, ml/min/1.73 m2 1.005 0.993–1.017 0.450
Fibrinogen, mg/dl 0.995 0.992–0.999 0.005
TAT, ng/ml 0.940 0.864–1.023 0.153
PIC, mg/ml 0.506 0.232–1.103 0.087
D-dimer, mg/dl 0.752 0.521–1.087 0.130
C-reactive protein, mg/dl 0.798 0.493–1.292 0.358
Drugs
Aspirin 1.896 0.881–4.081 0.102
Thienopyridines 0.650 0.256–1.652 0.650
Cilostazol 0.408 0.145–1.141 0.088
Beraprost 0.540 0.259–1.124 0.099
Sarpogrelate 1.689 0.408–6.995 0.469
Statin 1.096 0.580–2.071 0.778
ACE/ARB 1.279 0.703–2.327 0.420
Beta-blocker 1.148 0.485–2.717 0.753
Ca antagonist 0.741 0.410–1.340 0.321
Warfarin 1.677 0.828–3.398 0.151
Continued in the next column
TABLE 2 Continued
Risk Factor HR 95% CI p Value
Multivariate analysis
MLA, post-procedure 0.955 0.920–0.991 0.016
In-stent thrombosis 9.061 3.129–26.240 <0.001
Antiplatelet discontinuation 10.980 3.269–36.881 <0.001
Calciﬁed lesion 2.412 1.114–5.223 0.026
CI ¼ conﬁdence interval; EVT ¼ endovascular treatment; HR ¼ hazard ratio;
TASC-II ¼ TransAtlantic Inter-Society Consensus II; other abbreviations as in
Table 1.
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1897for individual factors in a Cox univariate analysis.
Factors with p < 0.05 in this analysis were used in a
multivariate Cox regression model with a Wald test
to determine predictors for endpoints. IBM SPSS
Statistics version 22.0 (IBM Corp., Armonk, New York)
was used for all calculations. Individual differences
were considered to be signiﬁcant for p < 0.05.
RESULTS
PATIENT CHARACTERISTICS. The subjects were 455
PAD patients of average age 71.8  8.5 years. The
patients had a total of 507 lesions. The characteristics
of all cases and those of cases with type A/B and type
C/D lesions are shown in Table 1. The rates of CLI and
chronic total occlusion (CTO) were higher for type C/D
lesions than for type A/B lesions. The initial success
rates were 97.2% (493 of 507) in all subjects, and
99.6%, 97.0%, 98.1%, and 91.1% in lesion types A, B,
C, and D, respectively. The initial success rate for type
C/D lesions was signiﬁcantly lower than that for
type A/B lesions (Table 1) (p ¼ 0.002). For 8 of the
14 lesions with an unsuccessful initial outcome, the
guidewire could not be passed through the lesion. All
such lesions were calciﬁed CTO lesions. Other reasons
for unsuccessful results included in-stent thrombus
protrusion or a heavily calciﬁed lesion, and there
were 3 lesions in which residual stenosis <30% was
not achieved. In addition, wire perforation occurred
in 2 subjects, and major dissection due to sheath
insertion occurred in 1 subject. In subjects with suc-
cessful EVT, improvement of symptoms was observed
in all cases with intermittent claudication, but minor
amputation was performed for 2 subjects and major
amputation was required for 1 subject with CLI. Of the
patients with unsuccessful EVT, 12 underwent bypass
surgery. Other patients were treated using exercise
rehabilitation and medication.
COMPLICATIONS. Complications were observed in
18 cases (4.0%): wire perforation in 2, major dissec-
tion upon insertion of the sheath in 1, distal emboli in 5,
hematoma that prolonged the hospital stay in 5, and
FIGURE 3 Kaplan-
Freedom From MAC
Major adverse cardio
diac revascularization
MACE, any repeat re
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1898pseudoaneurysm in 5. There were no deaths. For the
2 subjects who developed distal emboli, surgical
resection of the thrombus was performed using
a Fogarty embolectomy catheter, and 3 patients
were treated with a thrombus aspiration catheter.
With regard to post-operative death, in-hospital mor-
tality was 0.2% (1 of 455), and 30-day mortality was
0.2% (1 of 455). The cause of death was acute
myocarditis.
LONG-TERM PATENCY. The median observation
period was 63 months (range 1 to 246 months). At 5, 10,
and 15 years, primary patencies were 87%, 83%, and
75% (Figure 1), primary-assisted patencies were 89%,
85%, and 82%, and secondary patencies were 92%,
91%, and 91%, respectively (Figure 1). The 5-, 10-, and
15-year primary patencies were 90%, 87%, and 79% in
type A, 84%, 77%, and 69% in type B, 85%, 78%, and
78% in type C, and 87%, 87%, and 70% in type D
lesions, respectively (Figure 2A), with no signiﬁcant
difference among TASC categories (p ¼ 0.149). The
5-, 10-, and 15-year primary patencies were 88%, 83%,
and 76% in type A/B, and 83%, 83%, and 70% in type
C/D lesions, respectively, with no signiﬁcant differ-
ence between these groups (Figure 2B) (p ¼ 0.406).
The results of Cox univariate analysis of individual
factors and calculated hazard ratios for restenosis
are shown in Table 2. Lesion length, pre- and
post-procedural angiographic stenosis rates, pre-
and post-procedural MLA, calciﬁed lesions, in-stentMeier Analysis of Overall Survival, Freedom From MACE, and
LE After Iliac Stenting
vascular events (MACE): all-cause death, myocardial infarction, car-
, and stroke; major adverse cardiovascular and limb events (MACLE):
vascularization for a limb, and major amputation.thrombosis, and discontinuation of antiplatelet ther-
apy were found to be signiﬁcant factors associated
with restenosis. In Cox multivariate analysis, post-
procedural MLA, in-stent thrombosis, antiplatelet
therapy discontinuation, and calciﬁed lesions were
independent predictors of primary patency. Overall,
7 patients discontinued antiplatelet agents with
medical advice for major surgery or bleeding, and
5 patients self-discontinued. Restenosis occurred in
4 of the self-discontinued patients and in 1 case dis-
continued for major bleeding.
LONG-TERM SURVIVAL. There were 158 (34.7%)
deaths during follow-up due to cardiac or major
vascular disease (n ¼ 50, 31.6%), cerebrovascular
disease (n ¼ 28, 17.7%), malignancy (n ¼ 36, 22.8%),
pneumonia (n ¼ 31, 19.6%), renal failure (n ¼ 5, 3.2%),
and other causes (8 patients, 5.1%). At 5, 10, and 15
years, the overall survival rates were 82%, 56%, and
40% (Figure 3), freedom from MACE was 71%, 44%,
and 25%, and freedom from MACLE was 57%, 29%,
and 14%, respectively (p < 0.001) (Figure 3). The 5-,
10-, and 15-year overall survival rates were 83%, 58%,
and 42% in type A/B, and 76%, 47%, and 23% in type
C/D lesions, respectively, with a tendency for lower
overall survival in cases with type C/D lesions (p ¼
0.088). The 5-, 10-, and 15-year freedom from MACE
rates were 72%, 48%, and 28% in type A/B, and 68%,
31%, and 21% in type C/D lesions, respectively, with
no signiﬁcant difference between the groups (p ¼
0.144). The 5-, 10-, and 15-year freedom from MACLE
rates were 58%, 30%, and 14% in type A/B, and 54%,
25%, and 13% in type C/D lesions, respectively, also
with no signiﬁcant difference between the groups
(p ¼ 0.409).
The results of Cox univariate analysis of individual
factors are shown in Table 3. In multivariate analysis
using signiﬁcant risk factors in univariate analysis,
age, CLI, diabetes mellitus, hemodialysis, and higher
D-dimer level were found to be independent pre-
dictors of all-cause mortality (Table 3).
DISCUSSION
There has been no previous comparison of 15-year
patency and life expectancy among TASC categories
after iliac stenting. In primary or selective stenting for
type C/D iliac artery lesions, recent meta-analyses
have found an initial success rate of 86% to 100%
(2,3,18). The initial success rate in the current study
was similarly favorable, except for type D lesions.
This may be because there was a high incidence of
severe calciﬁed CTO lesions in type D cases. In pri-
mary stenting, there was no correlation between
TABLE 3 Predictive Risk for 15-Year All-Cause Mortality by
Cox Univariate and Multivariate Analysis
Risk Factor HR 95% CI p Value
Univariate analysis
Age, yrs 1.007 1.005–1.100 <0.001
Male 1.236 0.682–2.243 0.485
ABI 0.472 0.182–1.223 0.122
BMI 0.942 0.891–0.997 0.037
CLI 2.813 1.694–4.670 <0.001
TASC, A/B/C/D 1.132 0.968–1.324 0.119
Lesion length, cm 1.011 0.975–1.048 0.541
Antiplatelet discontinuation 1.245 0.839–1.847 0.276
Risk factors
Diabetes mellitus 1.779 1.206–2.624 0.004
Hypertension 1.013 0.717–1.433 0.940
Coronary artery disease 0.857 0.607–1.210 0.381
Cerebral infarction 1.449 0.930–2.259 0.101
Smoking 0.759 0.433–1.003 0.059
Dyslipidemia 1.506 0.854–2.654 0.157
Hemodialysis 2.975 1.431–6.186 0.003
Laboratory data
eGFR, ml/min/1.73 m2 0.984 0.974–0.994 0.001
Fibrinogen, mg/dl 1.002 1.000–1.004 0.095
TAT, ng/ml 1.035 1.018–1.052 <0.001
PIC, mg/ml 1.578 1.265–1.969 <0.001
D-dimer, mg/dl 1.350 1.239–1.472 <0.001
C-reactive protein, mg/dl 1.107 0.967–1.268 0.141
Drugs
Aspirin 0.620 0.440–0.873 0.006
Thienopyridines 1.198 0.804–1.786 0.374
Cilostazol 0.850 0.588–1.228 0.386
Beraprost 1.029 0.733–1.444 0.868
Sarpogrelate 1.610 0.656–3.954 0.299
Statin 0.515 0.328–0.806 0.004
ACE/ARB 0.782 0.545–1.124 0.184
b-Blocker 0.864 0.512–1.458 0.585
Ca antagonist 0.996 0.709–1.399 0.980
Warfarin 1.522 1.009–2.298 0.045
Multivariate analysis
Age, yrs 1.081 1.055–1.107 <0.001
CLI 1.994 1.146–3.469 0.015
Diabetes mellitus 1.856 1.13–2.887 0.006
Hemodialysis 3.333 1.484–7.487 0.004
D-dimer, mg/dl 1.228 1.107–1.361 <0.001
BMI ¼ body mass index; other abbreviations as in Tables 1 and 2.
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1899outcome and TASC category, and 15-year patency was
approximately 75% for all lesions. For comparison, a
meta-analysis found 5-year primary patencies of
67.1% and 63.0% for primary and selective stenting
for type C/D lesions, respectively (3). Thus, our
15-year patency was more favorable than data from
the meta-analysis for 5-year primary patency.
In Cox multivariate analysis, post-procedural MLA,
in-stent thrombosis, discontinuation of antiplatelet
therapy, and calciﬁed lesions were independentpredictors of primary patency. The high-resolution
cross-sectional IVUS image clearly identiﬁes in-stent
thrombosis and calciﬁcation. Platelets play a central
role in the pathogenesis of atherothrombosis (19), and
early and late stent thromboses are causes of stent
restenosis in the coronary artery (20). Residual
in-stent thrombosis in iliac stenting may also be a
cause of restenosis, and calciﬁed lesions are a re-
fractory risk with a high rate of restenosis following
coronary stenting (21). Recent experimental studies
have shown that chronic inﬂammation is closely
associated with development of coronary calciﬁcation
and possible development of neointimal hyperplasia
(22). Local hemodynamic factors, particularly low
endothelial shear stress, are causes of in-stent reste-
nosis and stent thrombosis (23), and calciﬁed lesions
may modify the stent ﬁgure and derange the shear
stress to increase neointimal proliferation.
Discontinuation of antiplatelet therapy was another
cause of restenosis in long-term patency. Self-
discontinuation is a serious problem in more than
5-year follow-up after EVT. The reasons for self-
discontinuation include adverse effects, cost, and
perception that medication is not needed (24). Many
chronically useddrugs are prescribedprophylactically,
in the absence of symptoms, and most patients may
decide to use their medication only for a limited period
of time, based on a lack of information (25). Older
patients have been found to be less likely to persist
with drugs after an acute coronary event at 3-month
follow-up (24). Because patients with PAD are older
than thosewith coronary disease,maintenance of drug
compliance may be particularly important after EVT.
The 15-year survival rate was higher than the re-
ported life expectancy in patients with PAD (1,12). This
may be because there were relatively few patients with
CLI in the current study. In multivariate Cox analysis
for life expectancy, age, CLI, diabetes mellitus, he-
modialysis, and higher D-dimer were independent
predictors for all-cause mortality. Mortality is strongly
correlated with CLI and ankle brachial pressure index
(as a measure of the severity of PAD), and diabetes
mellitus also increases the risks of PAD and cardio-
vascular mortality (1,26,27). These consistent results
suggest that severe PAD and complication with dia-
betes mellitus involve extensive and severe degrees of
systemic atherosclerosis that are responsible for the
mortality caused by cardiovascular disease.
Hemodialysis was also found to be an independent
predictor of mortality. Several studies have suggested
that chronic kidney disease is a prognostic indicator
of cardiovascular disease (28,29) and O’Hare et al.
(30) found that renal dysfunction was a strong inde-
pendent predictor of mortality in CLI patients. We
PERSPECTIVES
WHAT IS KNOWN? Fifteen-year patency, factors
causing restenosis, and survival after endovascular
treatment with primary stenting guided by IVUS for
iliac artery lesions are unclear based on the TASC-II
classiﬁcation in peripheral arterial disease.
WHAT IS NEW? The 15-year primary patency
showed no signiﬁcant difference among TASC-II
categories. Post-procedural mean lumen area, in-
stent thrombosis, antiplatelet therapy discontinua-
tion, and calciﬁed lesions were predictors of primary
patency. Age, critical limb ischemia, diabetes, he-
modialysis, and D-dimer level were predictors of
overall survival.
WHAT IS NEXT? Further studies of long-term
patency and life expectancy are required for
IVUS-guided iliac stenting. New approaches are
needed to improve drug compliance after EVT in
patients with PAD.
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1900also found an association between D-dimer and all-
cause mortality. D-dimer is an end product of ﬁbri-
nolysis that promotes the inﬂammatory cascade by
activating neutrophils and monocytes, inducing
secretion of inﬂammatory cytokines, and promoting
hepatic synthesis of acute-phase proteins (31). Plasma
D-dimer levels are also independently associated
with the presence of coronary artery disease (32).
Thus, a higher D-dimer level may be a cause of
increased mortality after EVT in patients with PAD.
STUDY LIMITATIONS. The limitations of this study
include the relatively small sample size and perfor-
mance of the study at a single facility. The serum
level of high-sensitivity C-reactive protein is also an
independent risk factor for cardiovascular disease
and restenosis (33,34), but only the serum level
of non–high-sensitivity C-reactive protein was mea-
sured in cases before 2004. Therefore, further studies
of long-term patency and life expectancy are required
in patients with PAD.
CONCLUSIONS
The 15-year patency was favorable after EVT in pa-
tients with PAD. Post-procedural MLA, in-stent
thrombosis, discontinuation of antiplatelet therapy,
and calciﬁed lesions were independent predictors of
primary patency. The 15-year survival rate was more
favorable than the reported life expectancy in
patients with PAD. Age, CLI, diabetes mellitus,
hemodialysis, and higher D-dimer levels were inde-
pendent predictors of all-cause mortality after EVT.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
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